{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}],"title":"No renal involvment"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Renal involvment, improved"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Renal involvment, profressed"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Renal involvment, died"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"12 months post-initiation of treatment following the 3 phase comprehensive treatment approach including induction with BD, followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.","groups":[{"description":"Participants with newly diagnosed AL amyloidosis","id":"OG000","title":"Amyloidosis"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"12 months","title":"Organ Response - Renal Involvement at 12 Months","type":"SECONDARY","unitOfMeasure":"Participants"}